Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL10949111 | 0.92 | CA2 (0.37) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL344 | 0.91 | CA2 (0.41) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL27892503 | 0.91 | CA2 (0.41) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| Water SCHEMBL581158 | 0.87 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| Fluoride SCHEMBL1594462 | 0.87 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL11421274 | 0.87 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| Water SCHEMBL18544564 | 0.87 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL7149277 | 0.87 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL11800353 | 0.87 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL9473581 | 0.87 | CA2 (0.39) | CA2CES2ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1602662-B1 | METHOD OF OBTAINING 17ALPHA-ACETOXY-11BETA-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE | CRYSTAL PHARMA SAU (ES) | 2014-04-23 | — | — | EP | disclosed |
| EP-2348033-A2 | Process for obtaining 17alfa-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione | Crystal Pharma, S.L.U. (ES) | 2011-07-27 | — | — | EP | disclosed |
| US-20060247452-A1 | Method for obtaining 17sg(a)-acetoxy-11$g(b)-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione | CRYSTAL PHARMA, S.A. (ES) | 2006-11-02 | — | — | US | disclosed |
| EP-1602662-A1 | METHOD OF OBTAINING 17ALPHA-ACETOXY-11BETA-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE | Crystal Pharma, S.A. (ES) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247452-A1 | Method for obtaining 17sg(a)-acetoxy-11$g(b)-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione | HSD17B13, HSD17B11, HSD17B3 | CA2 2670/4885CES2 2898/4885ALDH1A1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.